Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 318

Sort by

Sort Order Select

Journal Articles

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Juan C. Ramos, Joseph A. Sparano, Amy Chadburn, Erin G. Reid, Richard F. Ambinder, Eric R. Siegel, Page C. Moore, Paul G. Rubinstein, Christine M. Durand, Ethel Cesarman, David Aboulafia, Robert Baiocchi, Lee Ratner, Lawrence Kaplan, Adam A. Capoferri, Jeannette Y. Lee, Ronald Mitsuyasu, Ariela Noy

Blood (2020) 136 (11): 1284–1297.

https://doi.org/10.1182/blood.2019003959

Published: 2020

Includes: Supplemental data

Journal Articles

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

Christopher E. Wee, MD, Jilan Kubusek, PharmD, Irbaz Riaz, MDMMSc, Robert Wolf, PharmD, RPh, Julian R Molina, MD PhD, Naseema Gangat, MBBS

Blood (2019) 134 (Supplement_1): 2138.

https://doi.org/10.1182/blood-2019-127367

Published: 2019

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

Conventional Chemotherapy Treatment Induces Unique Patterns of Clonal Evolution in a North American Adult T Cell Leukemia/Lymphoma Cohort

Blood (2019) 134 (Supplement_1): 1551.

https://doi.org/10.1182/blood-2019-131107

Published: 2019

Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD

Blood (2019) 134 (Supplement_1): 1581.

https://doi.org/10.1182/blood-2019-128475

Published: 2019

Journal Articles

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

Carlyn Rose Tan, MD, Stefan K. Barta, MD MRCP, MS, Shelly Y. Lensing, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1595.

https://doi.org/10.1182/blood-2019-129702

Published: 2019

Journal Articles

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Blood (2019) 134 (Supplement_1): 487.

https://doi.org/10.1182/blood-2019-122298

Published: 2019

Journal Articles

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Vania Phuoc, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Bijal Shah, MD, Lubomir Sokol, MD PhD, Julio Chavez

Blood (2019) 134 (Supplement_1): 2898.

https://doi.org/10.1182/blood-2019-122393

Published: 2019

Journal Articles

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

Juan Carlos Ramos, MD BS, Richard F. Ambinder, MD, Joseph Sparano, MD, Jeannette Y Lee, PhD, Lawrence D Kaplan, MD, William Wachsman, MD PhD, David M. Aboulafia, MD, Ariela Noy, MD, Lee Ratner, MD PhD, David H. Henry, MD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Ronald T. Mitsuyasu, MD

Blood (2019) 134 (Supplement_1): 2872.

https://doi.org/10.1182/blood-2019-123558

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

Journal Articles

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Caspian Oliai, MD, Sven de Vos, MD PhD

Blood (2019) 134 (Supplement_1): 5360.

https://doi.org/10.1182/blood-2019-129371

Published: 2019

Journal Articles

R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results

Nelly G Gabeeva, PhD, Darya A Koroleva, Svetlana A Tatarnikova, Anna K Smolyaninova, Svetlana Smirnova, MD PhD, Elena E Nikulina, Alla M. Kovrigina, MD PhD, Andrey B Sudarikov, PhD DSc, Eugene E. Zvonkov, MD PhD, Valery G. Savchenko, MD PhD academician

Blood (2019) 134 (Supplement_1): 5334.

https://doi.org/10.1182/blood-2019-127944

Published: 2019

Journal Articles

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Prue Hardefeldt, MBBS, John Moore, MDFRACP,FRCPA, Sam Milliken, MBBS, FRACP, FRCPA, Keith Fay, FRCP,FRCPath,MB, Lavee Orly, MBBS, Eleni Mayson, FRACP, FRCPA, MBBS, MPhil, Barbara Withers, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2019) 134 (Supplement_1): 5336.

https://doi.org/10.1182/blood-2019-125154

Published: 2019

Journal Articles

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Lacey S. Williams, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 5697.

https://doi.org/10.1182/blood-2019-122932

Published: 2019

Journal Articles

Encouraging Outcomes with Intensive Chemotherapy for Patients with Primary Mediastinal B-Cell Lymphoma - a Swedish Lymphoma Register Study

Tove Wästerlid, MD PhD, George Z. Rassidakis, MD PhD Prof., Birgitta Sander, MD PhD Prof., Karin E. Smedby, MD PhD

Blood (2019) 134 (Supplement_1): 1618.

https://doi.org/10.1182/blood-2019-122819

Published: 2019

Journal Articles

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Francesca Montanari, MD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Jennifer Kimberly Lue, MD, Enrica Marchi, MD, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 2909.

https://doi.org/10.1182/blood-2019-131841

Published: 2019

Journal Articles

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Zachary D. Epstein-Peterson, MD, Paola Ghione, MD, Alison J. Moskowitz, MD, Parastoo B. Dahi, MD, Ahmet Dogan, MD PhD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, Miguel-Angel Perales, MD, Doris M Ponce, MD, David J. Straus, MD, Andrew D. Zelenetz, MD PhD, Craig S. Sauter, MD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2850.

https://doi.org/10.1182/blood-2019-125376

Published: 2019

Journal Articles

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

Louis-Bassett Porter, MD, Hanaa Shihadeh, Kim Dittus, MD PhD

Blood (2019) 134 (Supplement_1): 2116.

https://doi.org/10.1182/blood-2019-121534

Published: 2019

Journal Articles

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Daniel Anscher, MD, Ahmad El-Far, MD, Said M Baidas

Blood (2019) 134 (Supplement_1): 3417.

https://doi.org/10.1182/blood-2019-121558

Published: 2019

Journal Articles

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Helen Ma, MD, Enrica Marchi, MD, PhD, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 3486.

https://doi.org/10.1182/blood-2019-123587

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Risk Factors for Increased Length of Stay (LOS) in Patients with Hematological Malignancies Electively Admitted for Chemotherapy

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Conventional Chemotherapy Treatment Induces Unique Patterns of Clonal Evolution in a North American Adult T Cell Leukemia/Lymphoma Cohort

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

A Multicenter, Open-Label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma: AIDS Malignancy Consortium 105

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Response-Adapted Therapy with Infusional EPOCH Chemotherapy Plus Rituximab in HIV-Associated, B-Cell Non-Hodgkin's Lymphoma

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Case Report: Sustained Remission Achieved from Anti-CD19 CAR T Cell Therapy Despite Prior Treatment with Anti-CD19 Antibody Tafasitamab (MOR208) in a Patient with Relapsed and Refractory Diffuse Large B-Cell Lymphoma

R-m-NHL-BFM-90/R-EPOCH Protocol in the Treatment of Patients with Primary Mediastinal Lymphoma: First Results

Dose Adjusted R-EPOCH Does Not Improve Outcomes in High Grade B Cell Lymphoma with Double Expressor Status or Gain of MYC/BCL2

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Encouraging Outcomes with Intensive Chemotherapy for Patients with Primary Mediastinal B-Cell Lymphoma - a Swedish Lymphoma Register Study

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Retrospective Review of Appropriate Use of Antimicrobials and Anticoagulants in Patients Hospitalized for a Malignant Hematologic Condition

Utility of Daily Laboratories in Patients with Lymphoma Admitted for Inpatient Chemotherapy

Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only